News
Clinical Development of Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergic patients – from first-in-human to clinical validation in 3 studies
Affiliations Ralph Mösges, PhD, MD FAAAAI Esther Raskopf, PhD Silke Allekotte, PhD Mandy Cuevas, MD Enrique Fernandez-Caldas, PhD José. L. Subiza, MD, PhD...
Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is safe and well tolerated – data from 3 sequential trials
Affiliations Silke Allekotte, PhD Esther Raskopf, PhD Laura England Christian Neuhof Hacer Sahin, PhD Lea Radtke, PhD Christoph Zeyen Lea Decker Elena...
Mannan-conjugated birch pollen allergoids reduce the combined symptom and medication score in birch pollen allergic patients already in the first treatment year and further decreases with prolonged treatment duration
https://clincompetence.de/wp-content/uploads/2023/03/T502_Poster_CSMS_AAAAI_2023.pdfRationale:
The success of allergen immunotherapy for the treatment of allergic rhinoconjunctivitis is most evident during the respective pollen season. Here, we evaluated the combined symptom and medication score (CSMS) from 3 studies in patients with allergic rhinoconjunctivitis treated with mannan-conjugated birch pollen allergoids (T502).
Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids shows long-term effects already after 2 years of treatment by inducing a significant immune response in birch pollen allergic patients
Affiliations Esther Raskopf, PhD Laura England Hacer Sahin, PhD Lea Radtke, PhD Christoph Zeyen Lea Decker Friederike Hüffmeier Elena Xenofontos Mandy Cuevas,...
EAACI Prague, 1-3 July 2022
CCC presents results of two-year treatment of birch pollen allergy with mannan-conjugated allergoids. CCC presents first results of a two-year...